TuHURA Biosciences, Inc.
NASDAQ:HURABiotechnology
+$0.14 today
- Market cap
- $87.31M
- Beta
- 0.01
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.52
Volume 0.19M
Average 0.85M
HURA Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
TuHURA Biosciences, Inc.NASDAQ: HURA
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation outflow shrinks to $0
Q1 FY2026 stock-based compensation was $0, compared with $1.42M a year earlier. Trailing-twelve-month stock-based compensation was $5M. Over 3 fiscal years it compounded at +208.8% a year.
Context
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly stock-based compensation holds near $0 or moves back toward the trailing-twelve-month quarterly average of $1.25M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 6.42M USD
- Year-over-year change
- +228.0%
- 4-year CAGR
- +77.0%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.42M | +228.0% |
| FY2024 | 2024-12-31 | 1.96M | +309.0% |
| FY2023 | 2023-12-31 | 478.89K | +119.4% |
| FY2022 | 2022-12-31 | 218.28K | -66.7% |
| FY2021 | 2021-12-31 | 654.53K | — |
Stock-Based Compensation vs competitors
How HURA compares with its peers on the latest reported figures
- HURA's LTM Mar 2026 stock-based compensation of $5M is the 5th largest of the 9 companies compared; the peer median is $6.86M.
- Over three fiscal years its annual growth of +208.8% compares with a peer median of -19.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $12.88M | -49.1% | -22.9% | 85.6% | |
| LTM Mar 2026 | $10.29M | -14.6% | -1.8% | 8.3% | |
| LTM Mar 2026 | $9.79M | -43.4% | -24.8% | 853.3% | |
| LTM Mar 2026 | $9.77M | +1.5% | +47.6% | — | |
| LTM Mar 2026 | $5M | — | +208.8% | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $3.95M | +20.1% | +23.4% | 33.0% |
| LTM Mar 2026 | $3.88M | -47.0% | -22.0% | 7.1% | |
| LTM Mar 2026 | $3.06M | -44.1% | -45.0% | — | |
| LTM Mar 2026 | $1.83M | -42.1% | -16.4% | — | |
| Peer median (excluding HURA) | $6.86M | -42.8% | -19.2% | 33.0% | |
Competitors are the stored peer set for HURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (7.02M) | (9.37M) | (29.32M) | (21.68M) | (30.05M) |
| Depreciation & Amortization | 380.69K | 373.09K | 177.38K | 116.71K | 71.27K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 654.53K | 218.28K | 478.89K | 1.96M | 6.42M |
| Change in Working Capital | (55K) | 1.56M | 486.92K | 3.29M | (3.15M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | (55K) | 1.56M | 486.92K | 3.29M | (3.15M) |
| Other Non-Cash Items | (527.06K) | (294.07K) | 21M | 1.59M | (924.51K) |
| Operating Cash Flow | (6.56M) | (7.51M) | (11.95M) | (14.73M) | (27.63M) |
| Capital Expenditures | (3.28K) | (232K) | (79.22K) | (57.91K) | (76.08K) |
| Acquisitions (Net) | 0 | 0 | (1.22M) | (5.99M) | (1.26M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (3.28K) | (36.28K) | (1.3M) | (6.05M) | (1.34M) |
| Debt Repayment | 294.07K | (350K) | 2.69M | 28.57M | 616.98K |
| Common Stock Issued | 5.6M | 1.9M | 10.58M | 5M | 21.92M |
| Common Stock Repurchased | 0 | 0 | (24.75K) | 0 | 0 |
| Dividends Paid | (8K) | (8K) | (6K) | 0 | (8.36K) |
| Other Financing Activities | 8K | 0 | 0 | (3.8M) | (2.61M) |
| Financing Cash Flow | 7.04M | 16.25M | 2.66M | 29.77M | 19.93M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 477.91K | 8.71M | (10.59M) | 8.99M | (9.04M) |
| Free Cash Flow | (6.57M) | (7.54M) | (12.03M) | (14.79M) | (27.71M) |
TuHURA Biosciences, Inc.
NASDAQ:HURA
Intrinsic Alpha fair value
Locked
Current Price
$1.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.